DWTX
HEALTHCAREVirios Therapeutics Inc
$1.65+0.21 (+14.58%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DWTX Today?
No stock-specific AI insight has been generated for DWTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.28$9.50
$1.65
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-7.13
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume252K
Avg Volume (10D)—
Shares Outstanding33.4M
DWTX News
20 articles- Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026Yahoo Finance·May 7, 2026
- Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100MYahoo Finance·Apr 23, 2026
- Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug ApprovalYahoo Finance·Apr 21, 2026
- Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and NeuropathyYahoo Finance·Apr 15, 2026
- DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26Yahoo Finance·Mar 23, 2026
- Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 18, 2026
- CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines DevelopmentYahoo Finance·Mar 10, 2026
- DWTX: Financing Secures Funding Through Phase 2b Data ReadoutYahoo Finance·Feb 2, 2026
- Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026Yahoo Finance·Feb 2, 2026
- Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b DevelopmentYahoo Finance·Jan 12, 2026
- DWTX: Positive Interim Results for Halneuron® Phase 2b Trial in CINP; Raising Valuation to $15Yahoo Finance·Dec 30, 2025
- Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With HalneuronYahoo Finance·Dec 22, 2025
- Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic PainYahoo Finance·Dec 22, 2025
- Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045Yahoo Finance·Dec 2, 2025
- Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025Yahoo Finance·Nov 11, 2025
- DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25…Yahoo Finance·Nov 10, 2025
- Dogwood Therapeutics Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 6, 2025
- Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025Yahoo Finance·Oct 30, 2025
- Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025Yahoo Finance·Oct 14, 2025
- DWTX: Licenses SP16 for Treatment of Cancer Related Pain…Yahoo Finance·Oct 10, 2025
All 20 articles loaded
Price Data
Open$1.43
Previous Close$1.44
Day High$1.54
Day Low$1.41
52 Week High$9.50
52 Week Low$1.28
52-Week Range
$1.28$9.50
$1.65
Fundamentals
Market Cap$55M
P/E Ratio—
EPS$-7.13
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume252K
Avg Volume (10D)—
Shares Outstanding33.4M
About Virios Therapeutics Inc
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—